[Towards a better use of midazolam in end of life: A survey in a department of medical oncology].

CONCLUSION: Although limited justifications in midazolam prescriptions could have resulted in an overestimate of sedation and in an underestimate of titrations, current guideline are not enough applied in routine, especially regarding the necessity of a pluridisciplinary decision-making. A list of requirements before midazolam initiation is suggested, to increase the adherence to guidelines. Our results highlight the necessity of a better midazolam use in life-end sedations.
PMID: 29150095 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - November 14, 2017 Category: Cancer & Oncology Authors: Beneton A, Vallard A, Brosse C, Poenou G, Pacaut C, Magné N, Morisson S Tags: Bull Cancer Source Type: research